文献速递药物相互作用

莫达非尼作为代谢性药物相互作用 perpetrator 的评估:基于模型知情鸡尾酒反应表型试验

Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol.
PubMed 文献 · Br J Clin Pharmacol · 2018-01-10

本研究采用单中心、开放标签、单序列鸡尾酒药物相互作用试验,在单次及稳态莫达非尼给药后评估其对CYP450活性的影响。结果显示单次200 mg莫达非尼仅使奥美拉唑AUC比值升高至1.36,稳态给药后奥美拉唑AUC比值升至1.90、咪达唑仑降至0.66、右美沙芬降至0.79。结论提示莫达非尼与主要经CYP2C19或CYP3A4清除的药物合用时需考虑临床相关代谢性药物相互作用风险。

要点

  • 单次莫达非尼200 mg仅显著抑制CYP2C19(奥美拉唑AUC比值1.36)。
  • 稳态莫达非尼增强CYP2C19抑制(奥美拉唑AUC比值1.90)并诱导CYP3A4(咪达唑仑AUC比值0.66)。
  • 合用时需关注经CYP2C19或CYP3A4主要清除药物的相互作用风险。

核心结论

  • 莫达非尼单次给药或稳态给药均可能作为perpetrator引起临床相关代谢性药物相互作用,主要涉及CYP2C19通路;稳态给药还涉及CYP3A4通路。

研究设计与样本

  • 单中心、开放标签、单序列鸡尾酒药物相互作用试验。
  • 受试者在第0、2、8天口服含100 mg咖啡因、30 mg右美沙芬、25 mg氯沙坦、1 mg咪达唑仑和20 mg肠溶奥美拉唑的鸡尾酒。
  • 第2天至第8天每日早晨口服莫达非尼200 mg。
  • 鸡尾酒给药前及给药后6小时内采集定时血样。

主要发现

  • 单次200 mg莫达非尼后,咖啡因、右美沙芬、氯沙坦、咪达唑仑和奥美拉唑的AUC比值(均值±95%CI)分别为0.95(±0.08)、1.01(±0.35)、0.97(±0.10)、0.98(±0.10)和1.36(±0.06)。
  • 莫达非尼稳态(200 mg用7天)后,上述AUC比值分别为0.90(±0.16)、0.79(±0.09)、0.98(±0.11)、0.66(±0.12)和1.90(±0.53)。

临床怎么用

  • 莫达非尼单次或稳态给药时,与主要经CYP2C19清除的药物合用时需考虑相互作用风险。
  • 莫达非尼稳态给药时,与主要经CYP3A4清除的药物合用时也需考虑相互作用风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To evaluate the capacity for modafinil to be a perpetrator of metabolic drug-drug interactions by altering cytochrome P450 activity following a single dose and dosing to steady state. METHODS: A single centre, open label, single sequence cocktail drug interaction trial. On days 0, 2 and 8 participants were administered an oral drug cocktail comprising 100 mg caffeine, 30 mg dextromethorphan, 25 mg losartan, 1 mg midazolam and 20 mg enteric-coated omeprazole. Timed blood samples were collected prior to and for up to 6 h post cocktail dosing. Between days 2 and 8 participants orally self-administered 200 mg modafinil each morning. RESULTS: Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively. Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively. CONCLUSIONS: These data support consideration of the risk of clinically relevant metabolic drug-drug interactions perpetrated by modafinil when this drug is co-administered with drugs that are primarily cleared by CYP2C19 (single modafinil dose or steady state modafinil dosing) or CYP3A4 (steady state modafinil dosing only) catalysed metabolic pathways.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Rowland A, van Dyk M, Warncken D, et al. Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. Br J Clin Pharmacol. 2018. PMID: 29178272. doi:10.1111/bcp.13478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。